Insiders · ATHA

ATHA insider transactions

Athira Pharma Inc. (ATHA) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

ATHA insiders

Everyone who has filed a Form 3, 4, 5 or 144 at Athira Pharma Inc., latest first. Follow anyone to get their next filing.

• Mark James LittonOfficer
• Martin Javier SanOfficer
• Mark WorthingtonOfficer

Recent Form 3, 4, and 5 filings for ATHA

• 310d
  CHIEF MEDICAL OFFICER San Martin Javier converted options into 4,667 shares and sold $11,311 worth of shares (1,644 units at $6.88), increasing direct ownership by 42% to 10,189 units (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 310d
  President and CEO Litton Mark James sold $17,792 worth of shares (2,586 units at $6.88) and converted options into 10,834 shares, increasing direct ownership by 25% to 40,828 units (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 310d
  Chief Financial Officer Renninger Robert was granted 1,000 shares, converted options into 1,236 shares and sold $2,043 worth of shares (297 units at $6.88), increasing direct ownership by 18% to 12,857 units (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 310d
  CHIEF SCIENTIFIC OFFICER Church Kevin was granted 1,000 shares, converted options into 3,667 shares and sold $6,027 worth of shares (876 units at $6.88), increasing direct ownership by 22% to 20,681 units (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 310d
  General Counsel and CCO Worthington Mark converted options into 3,667 shares and sold $6,027 worth of shares (876 units at $6.88), increasing direct ownership by 25% to 13,978 units (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 317d
  SEC Form 4 filed by Chief Financial Officer Renninger Robert

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 317d
  SEC Form 4 filed by President and CEO Litton Mark James

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 317d
  SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Church Kevin

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 317d
  SEC Form 4 filed by CHIEF MEDICAL OFFICER San Martin Javier

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 317d
  SEC Form 4 filed by General Counsel and CCO Worthington Mark

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 323d
  Director Perceptive Advisors Llc was granted 1,319,026 shares (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 497d
  CHIEF SCIENTIFIC OFFICER Church Kevin was granted 10,000 shares, converted options into 36,666 shares and sold $2,502 worth of shares (8,526 units at $0.29), increasing direct ownership by 29% to 168,901 units (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 497d
  President and CEO Litton Mark James converted options into 108,334 shares and sold $7,374 worth of shares (25,123 units at $0.29), increasing direct ownership by 34% to 325,802 units (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 497d
  CHIEF MEDICAL OFFICER San Martin Javier converted options into 46,666 shares and sold $3,182 worth of shares (10,842 units at $0.29), increasing direct ownership by 100% to 71,665 units (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 497d
  General Counsel and CCO Worthington Mark converted options into 36,666 shares and sold $2,502 worth of shares (8,526 units at $0.29), increasing direct ownership by 34% to 111,875 units (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 497d
  SVP, Finance and Accounting Renninger Robert converted options into 12,359 shares, sold $850 worth of shares (2,897 units at $0.29) and was granted 10,000 shares, increasing direct ownership by 22% to 109,186 units (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 526d
  SEC Form 4 filed by Director Fluke John M Jr

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 526d
  SEC Form 4 filed by Director Panzara Michael A.

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 526d
  SEC Form 4 filed by Director Romano Kelly A

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 526d
  SEC Form 4 filed by Director Edelman Joseph

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 526d
  SEC Form 4 filed by Director Johnson James A

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 526d
  SEC Form 4 filed by Director Kosacz Barbara

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 526d
  SEC Form 4 filed by Director Pickering Grant

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 609d
  Amendment: SEC Form 4 filed by SVP, Finance and Accounting Renninger Robert

  4/A - Athira Pharma, Inc. (0001620463) (Issuer)
• 617d
  SEC Form 4 filed by SVP, Finance and Accounting Renninger Robert

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 617d
  SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Church Kevin

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 617d
  SEC Form 4 filed by President and CEO Litton Mark James

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 617d
  SEC Form 4 filed by CHIEF MEDICAL OFFICER San Martin Javier

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 617d
  SEC Form 4 filed by General Counsel and CCO Worthington Mark

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 677d
  CHIEF MEDICAL OFFICER San Martin Javier converted options into 46,667 shares and sold $6,083 worth of shares (10,826 units at $0.56) (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 677d
  President and CEO Litton Mark James converted options into 108,333 shares and sold $14,108 worth of shares (25,107 units at $0.56), increasing direct ownership by 52% to 242,591 units (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 677d
  CHIEF SCIENTIFIC OFFICER Church Kevin was granted 9,920 shares, converted options into 36,667 shares and sold $4,782 worth of shares (8,510 units at $0.56), increasing direct ownership by 41% to 130,761 units (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 677d
  VP of Finance Renninger Robert was granted 3,651 shares, converted options into 12,359 shares and sold $1,619 worth of shares (2,881 units at $0.56), increasing direct ownership by 17% to 89,724 units (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 677d
  General Counsel and CCO Worthington Mark was granted 3,651 shares, converted options into 36,667 shares and sold $4,782 worth of shares (8,510 units at $0.56), increasing direct ownership by 61% to 83,735 units (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 769d
  Amendment: SEC Form 4 filed by President and CEO Litton Mark James

  4/A - Athira Pharma, Inc. (0001620463) (Issuer)
• 769d
  SEC Form 4 filed by VP of Finance Renninger Robert

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 769d
  SEC Form 4 filed by CHIEF MEDICAL OFFICER San Martin Javier

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 769d
  SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Church Kevin

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 769d
  SEC Form 4 filed by General Counsel and CCO Worthington Mark

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 769d
  SEC Form 4 filed by President and CEO Litton Mark James

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 769d
  New insider Renninger Robert claimed ownership of 76,595 shares (SEC Form 3)

  3 - Athira Pharma, Inc. (0001620463) (Issuer)
• 797d
  CFO and Chief Business Officer Gengos Andrew was granted 15,000 shares and sold $720 worth of shares (1,272 units at $0.57), increasing direct ownership by 16% to 97,532 units (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 797d
  COO and CDO Lenington Rachel was granted 10,000 shares and sold $1,429 worth of shares (2,525 units at $0.57), increasing direct ownership by 56% to 20,870 units (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 797d
  CHIEF SCIENTIFIC OFFICER Church Kevin was granted 14,953 shares and sold $1,429 worth of shares (2,525 units at $0.57), increasing direct ownership by 15% to 92,684 units (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 797d
  GENERAL COUNSEL Worthington Mark was granted 20,000 shares and sold $1,429 worth of shares (2,525 units at $0.57), increasing direct ownership by 51% to 51,927 units (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 797d
  President and CEO Litton Mark James was granted 20,000 shares and sold $2,848 worth of shares (5,032 units at $0.57), increasing direct ownership by 10% to 159,365 units (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 869d
  Director Romano Kelly A bought $100,051 worth of shares (42,400 units at $2.36), increasing direct ownership by 111% to 80,715 units (SEC Form 4)

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 901d
  SEC Form 4 filed by Romano Kelly A

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 901d
  SEC Form 4 filed by Edelman Joseph

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 901d
  SEC Form 4 filed by Johnson James A

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 901d
  SEC Form 4 filed by Kosacz Barbara

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 901d
  SEC Form 4 filed by Panzara Michael A.

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 901d
  SEC Form 4 filed by Pickering Grant

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 901d
  SEC Form 4 filed by Fluke John M Jr

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 939d
  SEC Form 4 filed by San Martin Javier

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 939d
  SEC Form 3 filed by new insider San Martin Javier

  3 - Athira Pharma, Inc. (0001620463) (Issuer)
• 999d
  SEC Form 4 filed by Litton Mark James

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 999d
  SEC Form 4 filed by Worthington Mark

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 999d
  SEC Form 4 filed by Church Kevin

  4 - Athira Pharma, Inc. (0001620463) (Issuer)
• 999d
  SEC Form 4 filed by Gengos Andrew

  4 - Athira Pharma, Inc. (0001620463) (Issuer)